Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

781. Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril

Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril Economic impact of the reduced incidence of atrial fibrillation in patients with heart failure treated with enalapril Wagner M, Rindress D, Desjardins B, Meilleur M C, Ducharme A, Tardif J C Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the impact of enalapril on the incidence of atrial fibrillation (AF) in patients with heart failure (HF). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population

2005 NHS Economic Evaluation Database.

782. A hospital perspective on the cost-effectiveness of beta-blockade for prophylaxis of atrial fibrillation after cardiothoracic surgery

A hospital perspective on the cost-effectiveness of beta-blockade for prophylaxis of atrial fibrillation after cardiothoracic surgery Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 NHS Economic Evaluation Database.

783. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study Full Text available with Trip Pro

Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care study Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multi-site managed-care (...) with chronic non-valvular atrial fibrillation who were receiving warfarin. The eligibility criteria for the patients were: 18 years of age or older; treated with warfarin at an anticoagulation clinic for at least 30 days; evidence of atrial fibrillation in the medical chart, but no evidence of mitral stenosis, severe mitral insufficiency, or severe tricuspid regurgitation noted in echocardiography reports; and no participation in prospective clinical studies involving anticoagulation care during the study

2005 NHS Economic Evaluation Database.

784. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation Full Text available with Trip Pro

Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation O'Brien C L, Gage B F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three treatments for stroke prophylaxis in patients with chronic atrial fibrillation were investigated. The treatments were aspirin, adjusted-dose warfarin with an international normalised ratio (INR) of 2 to 3, and fixed-dose ximelagatran (36 mg twice per day). Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study

2005 NHS Economic Evaluation Database.

785. Ximelagatran cost effectiveness for stroke prevention in atrial fibrillation

Ximelagatran cost effectiveness for stroke prevention in atrial fibrillation Ximelagatran cost effectiveness for stroke prevention in atrial fibrillation Ximelagatran cost effectiveness for stroke prevention in atrial fibrillation Valiya S N, Bajorek B V Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology The use of ximelagatran, a new oral antithrombotic, for stroke prevention in non-valvular atrial fibrillation (AF). Ximelagatran was compared with warfarin and aspirin. The dosages assessed were 7.5 mg/day for warfarin, 100 mg/day for aspirin and 36 mg twice daily for ximelagatran. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population The hypothetical study population comprised

2005 NHS Economic Evaluation Database.

786. Catheter Ablation of Atrial Fibrillation</a>

Catheter Ablation of Atrial Fibrillation Catheter Ablation of Atrial Fibrillation We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Catheter Ablation of Atrial Fibrillation Share: Reading time less than 1 minute SBU Alert report no 2005-02 has been updated. The report, and the update, is available on Page updated April 18, 2016 Evidence

2005 Swedish Council on Technology Assessement

787. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. Full Text available with Trip Pro

Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. In-hospital administration of flecainide and propafenone in a single oral loading dose has been shown to be effective and superior to placebo in terminating atrial fibrillation. We evaluated the feasibility and the safety of self-administered oral loading of flecainide and propafenone in terminating atrial fibrillation of recent onset outside the hospital.We administered either flecainide (...) or propafenone orally to restore sinus rhythm in 268 patients with mild heart disease or none who came to the emergency room with atrial fibrillation of recent onset that was hemodynamically well tolerated. Of these patients, 58 (22 percent) were excluded from the study because of treatment failure or side effects. Out-of-hospital self-administration of flecainide or propafenone--the "pill-in-the-pocket" approach--after the onset of heart palpitations was evaluated in the remaining 210 patients (mean age

2004 NEJM

788. Catheter ablation for atrial fibrillation in congestive heart failure. (Abstract)

Catheter ablation for atrial fibrillation in congestive heart failure. Congestive heart failure and atrial fibrillation often coexist, and each adversely affects the other with respect to management and prognosis. We prospectively evaluated the effect of catheter ablation for atrial fibrillation on left ventricular function in patients with heart failure.We studied 58 consecutive patients with congestive heart failure and a left ventricular ejection fraction of less than 45 percent who were (...) undergoing catheter ablation for atrial fibrillation. We selected as controls 58 patients without congestive heart failure who were undergoing ablation for atrial fibrillation, matched according to age, sex, and classification of atrial fibrillation. We evaluated the patients' left ventricular function and dimensions, symptom score, exercise capacity, and quality of life at baseline and at months 1, 3, 6, and 12.After a mean (+/-SD) of 12+/-7 months, 78 percent of the patients with congestive heart

2004 NEJM

789. Obesity and the risk of new-onset atrial fibrillation. Full Text available with Trip Pro

Obesity and the risk of new-onset atrial fibrillation. Obesity is associated with atrial enlargement and ventricular diastolic dysfunction, both known predictors of atrial fibrillation (AF). However, it is unclear whether obesity is a risk factor for AF.To examine the association between body mass index (BMI) and the risk of developing AF.Prospective, community-based observational cohort in Framingham, Mass. We studied 5282 participants (mean age, 57 [SD, 13] years; 2898 women [55%]) without (...) baseline AF (electrocardiographic AF or arterial flutter). Body mass index (calculated as weight in kilograms divided by square of height in meters) was evaluated as both a continuous and a categorical variable (normal defined as <25.0; overweight, 25.0 to <30.0; and obese, > or =30.0). In addition to adjusting for clinical confounders by multivariable techniques, we also examined models including echocardiographic left atrial diameter to examine whether the influence of obesity was mediated by changes

2004 JAMA

790. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. (Abstract)

Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. The risk for atrial fibrillation-associated stroke increases at low anticoagulation intensities. However, higher intensities increase hemorrhage risk. Optimal use of warfarin for atrial fibrillation requires precise information on the risk for intracranial hemorrhage as a function of patient age and anticoagulation intensity.To examine the relationship of age (...) focus on maintaining INRs in the 2.0 to 3.0 range, even in elderly patients with atrial fibrillation, rather than targeting INRs less than 2.0. Similarly, INRs of 3.5 or greater should be avoided.

2004 Annals of Internal Medicine

791. Cost-effectiveness of rhythm versus rate control in atrial fibrillation. (Abstract)

Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Atrial fibrillation is the most common type of sustained cardiac arrhythmia, but recent trials have identified no clear advantage of rhythm control over rate control. Consequently, economic factors often play a role in guiding treatment selection.To estimate the cost-effectiveness of rhythm-control versus rate-control strategies for atrial fibrillation in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (...) (AFFIRM).Retrospective economic evaluation. Nonparametric bootstrapping was used to estimate the distribution of incremental costs and effects on the cost-effectiveness plane.Data on survival and use of health care resources were obtained for all 4060 AFFIRM participants. Unit costs were estimated from various U.S. databases.Patients with atrial fibrillation who were 65 years of age or who had other risk factors for stroke or death, similar to those enrolled in AFFIRM.Mean follow-up of 3.5 years.Third

2004 Annals of Internal Medicine

792. Is there a role for maintaining sinus rhythm in patients with atrial fibrillation? (Abstract)

Is there a role for maintaining sinus rhythm in patients with atrial fibrillation? Recent studies have indicated that outcomes in patients with atrial fibrillation who are managed with rate control and anticoagulation are similar to those in patients who have maintenance of sinus rhythm. These studies did not include important groups of patients with atrial fibrillation in whom antiarrhythmic therapy may be appropriate. This perspective argues for the maintenance of sinus rhythm and for the use

2004 Annals of Internal Medicine

793. Rate control was not inferior to rhythm control for recurrent persistent atrial fibrillation Full Text available with Trip Pro

Rate control was not inferior to rhythm control for recurrent persistent atrial fibrillation Rate control was not inferior to rhythm control for recurrent persistent atrial fibrillation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Rate control was not inferior to rhythm control for recurrent persistent atrial fibrillation Article Text Therapeutics Rate control was not inferior to rhythm control for recurrent persistent atrial

2004 Evidence-Based Medicine

794. Rhythm control strategies were not better than rate control strategies for atrial fibrillation Full Text available with Trip Pro

Rhythm control strategies were not better than rate control strategies for atrial fibrillation Rhythm control strategies were not better than rate control strategies for atrial fibrillation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Rhythm control strategies were not better than rate control strategies for atrial fibrillation Article Text Therapeutics Rhythm control strategies were not better than rate control strategies

2004 Evidence-Based Medicine

795. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. Full Text available with Trip Pro

Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. Atrial fibrillation (AF) is the most common cardiac dysrhythmia in the United States. Whereas rare cases of familial AF have been reported, it is unknown if AF among unselected individuals is a heritable condition.To determine whether parental AF increases the risk for the development of offspring AF.Prospective cohort study (1983-2002) within the Framingham Heart Study, a population-based epidemiologic study

2004 JAMA

796. A multicenter risk index for atrial fibrillation after cardiac surgery. Full Text available with Trip Pro

A multicenter risk index for atrial fibrillation after cardiac surgery. Atrial fibrillation is a common, but potentially preventable, complication following coronary artery bypass graft (CABG) surgery.To assess the nature and consequences of atrial fibrillation after CABG surgery and to develop a comprehensive risk index that can better identify patients at risk for atrial fibrillation.Prospective observational study of 4657 patients undergoing CABG surgery between November 1996 and June 2000 (...) at 70 centers located within 17 countries, selected using a systematic sampling technique. From a derivation cohort of 3093 patients, associations between predictor variables and postoperative atrial fibrillation were identified to develop a risk model, which was assessed in a validation cohort of 1564 patients.New-onset atrial fibrillation after CABG surgery.A total of 1503 patients (32.3%) developed atrial fibrillation after CABG surgery. Postoperative atrial fibrillation was associated

2004 JAMA

797. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. (Abstract)

Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. People with nonrheumatic atrial fibrillation (NRAF) who have had a transient ischaemic attack (TIA) or a minor ischaemic stroke are at high risk of recurrent stroke.The objective of this review was to assess the effect of anticoagulants for secondary prevention, after a stroke or TIA, in patients with NRAF.We searched the Cochrane Stroke Group trials

2004 Cochrane

798. Idraparinux sodium for prevention of stroke in patients with atrial fibrillation - horizon scanning review

Idraparinux sodium for prevention of stroke in patients with atrial fibrillation - horizon scanning review Idraparinux sodium for prevention of stroke in patients with atrial fibrillation - horizon scanning review Idraparinux sodium for prevention of stroke in patients with atrial fibrillation - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation NHSC. Idraparinux sodium for prevention of stroke in patients with atrial fibrillation - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2004 Authors' objectives This study aims to summarise the currently available evidence on idraparinux sodium for prevention of stroke in patients with atrial fibrillation. Authors' conclusions Idraparinux sodium (SanOrg-34006) is a long-acting antithrombotic agent in phase III clinical trials

2004 Health Technology Assessment (HTA) Database.

799. A systematic review of intraoperative ablation for the treatment of atrial fibrillation

A systematic review of intraoperative ablation for the treatment of atrial fibrillation A systematic review of intraoperative ablation for the treatment of atrial fibrillation A systematic review of intraoperative ablation for the treatment of atrial fibrillation Hazel S J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hazel S J (...) . A systematic review of intraoperative ablation for the treatment of atrial fibrillation. Stepney, SA: Australian Safety and Efficacy Register of New Interventional Procedures - Surgical (ASERNIP-S) 2004: 388 Authors' objectives The aim of this review was to assess the safety and efficacy of intraoperative surgical ablation techniques for the treatment of atrial fibrillation (AF) compared to other surgical procedures, including cardiac surgery (CS) alone, or the Maze-III procedure, the current gold standard

2004 Health Technology Assessment (HTA) Database.

800. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials

The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.